Moleculin Biotech Expands Global Patent Portfolio with Hong Kong Approval for Annamycin Reconstitution Method
New Hong Kong patent strengthens Moleculin’s intellectual property protection ahead of pivotal Phase 3 clinical data release for Annamycin
Moleculin Biotech has secured a key patent in Hong Kong covering its proprietary method of reconstituting liposomal Annamycin, extending its intellectual property protection through 2040. This milestone enhances the company’s global exclusivity strategy as it prepares for the upcoming release of Phase 3 clinical trial…